# BPC-157: What the Research Literature Actually Shows > BPC-157, the stable gastric pentadecapeptide, has accelerated tissue repair across decades of rodent studies. A chalkboard reading of the mechanism, the pharmacokinetics, and where the human evidence stops. A plain-English reading of the published literature on BPC-157: the angiogenesis mechanism, the pharmacokinetics, the tissue-repair findings, and an honest map of where the evidence stops. ## Start at the board: what BPC-157 is, in one lesson BPC-157 is a synthetic 15-amino-acid peptide that has accelerated tendon, gut, muscle, and vascular repair across decades of animal studies. The name stands for Body Protection Compound 157, and it is derived from a partial sequence of a protein isolated from human gastric juice [5]. Almost everything measured about it has been measured in rodents — a point this whole site keeps in view. The single most consistent finding in the literature is angiogenesis: in injured tissue, BPC-157 promotes the formation of new blood vessels [3]. The repair effects across skin, muscle, tendon, ligament, and bone are organized around that cytoprotective, vessel-building mechanism [5]. The peptide is often called a *stable gastric pentadecapeptide* because it is reported to remain stable in gastric juice [2]. The breadth of that [tendon and musculoskeletal repair research](/research-benefits) is real and reproducible across models. What the studies do *not* establish is just as important. Human evidence is limited to three small pilot studies, large controlled trials are lacking, and BPC-157 is not an approved drug anywhere [11]. A 2025 narrative review reads the same record and concludes it should be treated as investigational [11]. The [BPC-157 safety signals](/faq) so far are reassuring within a tiny dataset, which is not the same as proven safety. That tension — broad rodent evidence, thin human evidence — is the lesson worth learning first. The sections below walk through it, the [FDA 503A compounding category](/legal-status) is covered on its own page, and every quantitative claim is chalked to a citation you can check on the [full reference list](/references). ## What is BPC-157? BPC-157 (Body Protection Compound 157) is a stable gastric pentadecapeptide studied as a research peptide for cytoprotection and tissue repair; it is not an approved drug and is studied chiefly in animal models [11]. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fifteen-amino-acid chain with a molecular weight near 1419.53 Da [5]. It is a synthetic fragment, not a peptide that circulates naturally in the body. ## BPC-157, the Stable Gastric Pentadecapeptide The BPC-157 peptide is a chemically synthesized 15-amino-acid sequence derived from a partial sequence of the Body Protection Compound found in human gastric juice [5]. "Pentadecapeptide" simply means fifteen amino acids. Researchers call it a *stable gastric pentadecapeptide* because, unlike many peptides, it is reported to survive the acidic environment of gastric juice [2] — the property behind interest in oral routes. It is usually supplied as the acetate salt and carries the identifiers CAS 137525-51-0 and PubChem CID 108101. As a peptide it sits in the cytoprotective/regenerative research class rather than among hormones or approved medicines. The 2022 pharmacokinetic study confirmed it behaves predictably in the body — linear pharmacokinetics, a short elimination half-life, and rapid breakdown into small fragments that re-enter normal amino-acid metabolism [2]. The identity is settled; the open questions are about what it does in people, covered across the [BPC-157 research benefits](/research-benefits) and research pages. ## What does BPC-157 do in the body? In animal models, BPC-157 is described as a cytoprotective peptide whose repair effects are most consistently linked to angiogenesis. The pathway runs through up-regulation and internalization of the VEGFR2 receptor, with downstream Akt-eNOS (nitric-oxide) signaling [3]. New vessels mean better-perfused tissue, which is the through-line connecting its findings in tendon, gut, and ischemic muscle [3]. ## Is BPC-157 a growth hormone? No. BPC-157 is a synthetic 15-amino-acid pentadecapeptide, not a growth hormone [5]. One tendon-fibroblast line of research reports that it up-regulates the growth-hormone receptor in those cells, which is a distinct mechanism from being a hormone itself. The distinction matters: BPC-157 is studied as a tissue-repair peptide, not a hormone-replacement compound. ## How is BPC-157 made? BPC-157 is a synthetic peptide: a chemically manufactured 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of the Body Protection Compound found in human gastric juice [5]. It is often supplied as the acetate salt. It is assembled in a laboratory, not extracted from tissue, and is sold by research suppliers for laboratory use rather than as a finished medicine. --- A chalkboard reading of the BPC-157 research record — every figure chalked to its study, no clinic at the board and nothing here for sale.